NCI-H661Homo sapiens (Human)Cancer cell line

Also known as: NCIH661, H-661, H661

🤖 AI SummaryBased on 14 publications

Quick Overview

Human lung cancer cell line with known RB1 mutations and potential for drug sensitivity studies.

Detailed Summary

The NCI-H661 cell line is a human lung cancer cell line derived from a small cell lung cancer (SCLC) tumor. It is characterized by specific genetic alterations, including mutations in the RB1 gene, which is a critical tumor suppressor. These genetic features make it a valuable model for studying the molecular mechanisms of SCLC and for evaluating the efficacy of targeted therapies. The cell line has been used in various research studies to investigate the role of RB1 in cancer progression and to identify potential therapeutic targets. Its utility in drug sensitivity assays and molecular profiling makes it a key resource for cancer research.

Research Applications

Molecular profiling of SCLCRB1 mutation analysisDrug sensitivity studiesTargeted therapy development

Key Characteristics

RB1 gene mutationsSmall cell lung cancer originUsed in cancer research for drug screening
Generated on 6/17/2025

Basic Information

Database IDCVCL_1577
SpeciesHomo sapiens (Human)
Tissue SourceLymph node[UBERON:UBERON_0000029]

Donor Information

Age43
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseLung large cell carcinoma
LineageLung
SubtypeLarge Cell Lung Carcinoma
OncoTree CodeLCLC

DepMap Information

Source TypeATCC
Source IDACH-000853_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Ser215Ile (c.644G>T)Heterozygous-from parent cell line SNU-398
MutationSimpleTP53p.Arg158Leu (c.473G>T)Homozygous-PubMed=30737244
MutationSimpleLASP1p.Glu48Ter (c.142G>T)Heterozygous-Unknown, Unknown
MutationSimpleCDKN2Ac.457+1G>THomozygousSplice donor mutationUnknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10
D13S317
11
D16S539
12
D18S51
11
D19S433
13,14
D21S11
31,33.2
D2S1338
17
D3S1358
15,16
D5S818
11
D7S820
8,10
D8S1179
10
FGA
20
Penta D
11,13
Penta E
12,13
TH01
8
TPOX
8
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.

Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.

Cancer Genet. Cytogenet. 125:87-99(2001).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.

Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.

Br. J. Cancer 77:2162-2170(1998).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources